Truncating mutations in this gene activate its oncogenic potential and lead to increased proliferation of NRAS-mutated melanoma cells by activating the PI3K/AKT pathway and RAC1 (Deribe 2016). The gene discussed is PIK3CA; the disease is melanoma.